Money Peak: Healthcare Sector Report

October 25 - November 1, 2025

🔍 Market Overview
The healthcare sector recorded an increase of 0.967% for the reporting week, marking a positive turn after several challenging months. This recovery follows an underwhelming performance in the first half of 2025. Notably, the sector is displaying renewed upward momentum despite ongoing regulatory uncertainties and cost pressures in healthcare.

The week's performance was primarily driven by three key factors: first, strong quarterly results from leading pharmaceutical companies such as Merck & Co., Inc. and Johnson & Johnson; second, positive developments in drug trials, particularly in immunology and oncology; and third, a slight easing for insurers concerning medical cost trends. There were notable differences between the subsectors: while pharmaceutical companies with innovative therapies saw impressive gains, health insurers like UnitedHealth Group continued to grapple with increased medical costs and regulatory challenges.

This budding recovery comes at a time when the healthcare sector is historically undervalued compared to the broader market. With an average P/E ratio of 15.2 against 21.4 for the S&P 500, there are potentially attractive entry opportunities for long-term investors, supported by demographic trends and the ongoing medical innovation cycle.

📊 Subsector Performance Analysis
The development within the healthcare sector showed significant differences this week between various areas, reflecting the diverse challenges and opportunities in healthcare:

The pharmaceutical sector was the clear winner this week, led by Merck, whose quarterly results exceeded expectations, showing an impressive 4% year-over-year revenue growth to $17.28 billion. The flagship cancer drug Keytruda surpassed $8 billion in quarterly sales for the first time. AbbVie also impressed with strong immunology sales, raising total revenues to $15.78 billion despite stock declines on the reporting day.

In contrast, insurance companies like UnitedHealth Group experienced a decline, with a weekly loss of 0.9%, as analysts critically assessed ongoing challenges from increased medical costs and regulatory reviews. Deutsche Bank downgraded the stock from "Buy" to "Hold" with a price target set at $333.

Pfizer attracted particular attention with a weekly rise of 1.48%, mainly driven by the takeover battle for the biotech company Metsera, where Pfizer competes with Novo Nordisk. The Federal Trade Commission has already granted Pfizer early approval for the acquisition.

🔬 Key Developments and Innovations
The healthcare sector is currently experiencing a phase of accelerated innovation, which could have significant long-term impacts on treatment outcomes and business models. Particularly noteworthy are:

In immunology, new therapies are achieving remarkable success. Johnson & Johnson announced the first direct comparative study (EPIC study) between its IMAAVY™ and an alternative FcRn blocker in generalized myasthenia gravis. Additionally, pediatric patients treated with IMAAVY™ showed sustained reduction of immunoglobulin G and disease control without new safety concerns over 72 weeks.

AbbVie continues its success in immunology, with portfolio revenues of $7.89 billion this quarter compared to $7.05 billion in Q3 2024. This underscores the company's leading position in autoimmune diseases despite competitive pressure.

For inflammatory bowel diseases, there are also significant advancements: Johnson & Johnson's TREMFYA® (Guselkumab) demonstrated long-term remission in Crohn's disease after two years, with clinical remission rates exceeding 85% for both maintenance doses. Simultaneously, Icotrokinra, a novel oral peptide therapy blocking the IL-23 receptor, continued to show clinically meaningful results in ulcerative colitis after 28 weeks.

In psoriasis, Johnson & Johnson unveiled a new study highlighting unmet needs and a strong preference from patients and physicians for highly effective oral treatments with a favorable safety profile. Over 90% of patients currently receiving injections would be willing to switch to a new oral therapy with equivalent efficacy.

In oncology, Merck's Keytruda has achieved a significant milestone with quarterly sales exceeding $8 billion, representing a 10% increase over the previous year. This confirms the company's dominance in the field of immuno-oncology.

🏥 Regulatory Landscape and Market Challenges
The regulatory environment remains a key influence on the healthcare sector, with various developments presenting both opportunities and risks:

Medicare Advantage programs remain in the spotlight, with both UnitedHealth and CVS restructuring their businesses in this area, prioritizing profitability over size. This strategy reflects ongoing challenges in managing higher medical costs but could lead to more stable margins in the long term.

Legal risks remain a major factor for many healthcare companies. Johnson & Johnson continues to face lawsuits related to its talc products, with a jury recently awarding $20 million to the family of a mesothelioma patient. Simultaneously, Texas sued Johnson & Johnson and Kenvue, alleging they concealed risks of Tylenol related to autism.

The acquisition landscape remains active, with notable competition between Pfizer and Novo Nordisk for the US biotech company Metsera, which focuses on obesity. Pfizer has filed a lawsuit against Metsera and Novo Nordisk for violation of the merger agreement, underscoring the strategic importance of this area for large pharmaceutical companies.

Supply chain issues due to strikes on the West Coast continue to affect the medical technology industry, with some manufacturers reporting delays in component deliveries. This situation could lead to delays in product launches and potentially higher operating costs.

💰 Outlook and Investment Opportunities
As we enter the final weeks of 2025, the healthcare sector presents a picture of differentiated opportunities:

Historical trends favor a positive development in November, a month that traditionally offers strong returns for healthcare stocks. Since 1927, the sector has yielded positive returns in 83% of November months, with an average gain of 2.52%.

Valuations in the healthcare sector remain attractive by historical comparison, with an average P/E ratio significantly lower than that of the broader market. This undervaluation potentially offers interesting entry opportunities for long-term investors, especially in companies with robust innovation pipelines.

The sector continues to benefit from strong structural growth drivers, including an aging population, increasing healthcare spending (projected to reach $5.3 trillion by 2025), and ongoing medical innovations. These long-term factors could outweigh short-term regulatory uncertainties.

Differentiation between subsectors is likely to persist, with innovative pharmaceutical companies and biotechnology firms with strong pipelines appearing better positioned than health insurers still grappling with cost pressure.

Investment Recommendations for Investors:

1. Selective Approach to Pharma Investments: Focus on companies with strong pipelines in specialized areas such as immunology and oncology, where pricing power remains more resilient despite regulatory challenges. Companies like Merck and AbbVie have proven their ability to drive growth through innovation in this quarter.

2. Caution with Health Insurers: Closely monitor the development of medical cost trends before investing in this subsector. Recent results from UnitedHealth suggest some stabilization, but margin issues have not been fully overcome.

3. Long-term Positioning in Biotechnology: The sector shows signs of recovery in venture capital investments and clinical successes. Consider a phased engagement in this area, which could benefit from the current wave of innovation.

4. Consideration of Dividend Potential: In times of increased market volatility, healthcare companies with stable dividends like Johnson & Johnson (dividend yield: 2.69%) and Merck (dividend yield: 3.77%) offer attractive defensive characteristics while participating in long-term sector growth.

5. Monitoring M&A Activities: Acquisition activity could accelerate in the coming months as established companies seek to strengthen their pipelines. Merck indicated its readiness for deals over $15 billion, suggesting a potential increase in acquisitions in the sector.